The global incidence of #alkaptonuria (AKU) varies substantially. Overall, AKU affects ~1 in 250,000 to 1,000,000 individuals worldwide. https://www.nature.c
Cycle Pharmaceuticals Partners with LeMed for Exclusive Distribution of HARLIKU™ Treatment in the U.S. #United_States #Bronx #HARLIKU™ #Alkaptonuria #Cycle_Pharmaceuticals
🥳New issue means new cover image🥳
Ochronotic #pigmentation is shown within the perichondrium surrounding hyaline #cartilage from the secondary #bronchus of an individual with #alkaptonuria.
Hughes et al.'s investigation of alkaptonuria, available now: doi.org/10.1111/joa....
Glad this is finally out. Using pharmacokinetic modeling we show that #nitisinone, an FDA-approved drug 4 #Tyrosinemia & #Alkaptonuria, kills #Anopheles mosquitoes, outperforming #Ivermectin. Grateful to all primary author’s & fantastic collaborators!
www.science.org/doi/10.1126/...
🌍💙 today is #RareDiseaseDay — a moment to raise awareness and support research for rare conditions.We study #Alkaptonuria (AKU) - ochronosis. Rare diseases may be uncommon, but research is key to better care & solutions.
It is always an absolute pleasure to participate in #alkaptonuria patient workshops 😄 the last was held in November in #Liverpool (UK), organised by the AKU Society - see my new blog ⬇️
@livuniresearch.bsky.social @livuni-ilcams.bsky.social
www.liverpool.ac.uk/health-and-l...
New publication out in Journal of anatomy with details of tissues such as ear ossicles, TMJ and sclera not reported before #anatomy #journalofanatomy #alkaptonuria
Just in time for Christmas 🎄
New paper in @journalofanatomy.bsky.social
Insights into #ochronosis in the #raredisease #alkaptonuria, made possible through the invaluable gift of body donation. Such a privilege working on this project!
onlinelibrary.wiley.com/doi/full/10....